HIGH POINT, N.C. — vTv Therapeutics (NSDQ:VTVT), the High Point biopharmaceutical company, expects to complete Phase 2 of its Alzheimer’s disease study by 2021.
The clinical trial for azeliragon, a drug created by the company to slow or halt the progression of the disease, is now in its 20th year.
The company aims to achieve Food and Drug Administration approval within the next five to six years.
To read more about the study, results, and what it could mean for treating Alzheimer's, click here to read the full story on the Triad Business Journal's website.
